acastiAs a tolerant investor in ACST for many years I wish to raise the following point. ACST is cash poor and needs a partner.
Have ACST considered approaching one of the large Chinese pharma organizations.
China has enough health problems of it's own for which CarePre could be the answer to justify acquisition and this alone could support a purchase price that would satisfy most, if not all, investors.
Whether or not the FDA issue an NDA or not China would then have a product that would not only help Chinese patients but would also provide them with a product that has worldwide market potential.